Matches in Wikidata for { <http://www.wikidata.org/entity/Q60473093> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q60473093 description "im November 2011 veröffentlichter wissenschaftlicher Artikel" @default.
- Q60473093 description "wetenschappelijk artikel" @default.
- Q60473093 description "наукова стаття, опублікована в листопаді 2011" @default.
- Q60473093 name "PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model" @default.
- Q60473093 name "PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor" @default.
- Q60473093 type Item @default.
- Q60473093 label "PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model" @default.
- Q60473093 label "PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor" @default.
- Q60473093 prefLabel "PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model" @default.
- Q60473093 prefLabel "PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor" @default.
- Q60473093 P1433 Q60473093-93B66A54-39BE-41FD-8296-2638D37DE2CB @default.
- Q60473093 P1476 Q60473093-322973C9-1F93-4EDF-ADDD-C9ADF093EEC2 @default.
- Q60473093 P2093 Q60473093-36B7726B-A13B-42C8-AB13-A11437512932 @default.
- Q60473093 P304 Q60473093-443EB53F-1458-4DB1-9086-3D8231E6877C @default.
- Q60473093 P31 Q60473093-6869752B-9D38-4E01-9F91-0DE9F7E7B210 @default.
- Q60473093 P356 Q60473093-D3A04C3E-516E-4FB0-BD2C-D7C2CEECEEA8 @default.
- Q60473093 P433 Q60473093-942A5DFA-9E5A-451D-A561-536719822170 @default.
- Q60473093 P478 Q60473093-4929C65D-65AE-4FB9-A6FE-049B713584D1 @default.
- Q60473093 P50 Q60473093-C3A06040-9AFB-4431-9440-61D27FE5A5E0 @default.
- Q60473093 P50 Q60473093-D7D06EA4-3E9A-4819-9D9F-7B0AAB4DC15A @default.
- Q60473093 P577 Q60473093-02CA9D6B-655C-4A7B-94C4-C1B6B78E6E8D @default.
- Q60473093 P921 Q60473093-B01C9D78-36AF-41F9-992D-7C1DA78BCE83 @default.
- Q60473093 P921 Q60473093-B055E1F2-C416-4E74-A79F-AF7875F26054 @default.
- Q60473093 P921 Q60473093-C2965541-6D83-4610-96CF-38AFE61F41F0 @default.
- Q60473093 P356 J.JVAL.2011.08.1210 @default.
- Q60473093 P1433 Q15766908 @default.
- Q60473093 P1476 "PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model" @default.
- Q60473093 P2093 "A. Vergnenegre" @default.
- Q60473093 P304 "A454" @default.
- Q60473093 P31 Q13442814 @default.
- Q60473093 P356 "10.1016/J.JVAL.2011.08.1210" @default.
- Q60473093 P433 "7" @default.
- Q60473093 P478 "14" @default.
- Q60473093 P50 Q57027992 @default.
- Q60473093 P50 Q57314970 @default.
- Q60473093 P577 "2011-11-01T00:00:00Z" @default.
- Q60473093 P921 Q1519812 @default.
- Q60473093 P921 Q1754768 @default.
- Q60473093 P921 Q6771326 @default.